

# ANTICONVULSANTS

---

## Products Affected

### Step 2:

- APTIOM TABLET 200 MG ORAL
- APTIOM TABLET 400 MG ORAL
- APTIOM TABLET 600 MG ORAL
- APTIOM TABLET 800 MG ORAL
- DILANTIN CAPSULE 30 MG ORAL
- FYCOMPA SUSPENSION 0.5 MG/ML ORAL
- FYCOMPA TABLET 10 MG ORAL
- FYCOMPA TABLET 12 MG ORAL
- FYCOMPA TABLET 2 MG ORAL
- FYCOMPA TABLET 4 MG ORAL
- FYCOMPA TABLET 6 MG ORAL
- FYCOMPA TABLET 8 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- VALTOCO 10 MG DOSE LIQUID 10 MG/0.1ML NASAL
- VALTOCO 15 MG DOSE LIQUID THERAPY PACK 7.5 MG/0.1ML NASAL
- VALTOCO 20 MG DOSE LIQUID THERAPY PACK 10 MG/0.1ML NASAL
- VALTOCO 5 MG DOSE LIQUID 5 MG/0.1ML NASAL

Formulary ID: 24452 version 10

Last Updated: 04/01/2024

Effective: 04/01/2024

H1993\_Formulary\_2024\_C

## Details

|                 |  |
|-----------------|--|
| <b>Criteria</b> | Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of a generic formulary anticonvulsant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary anticonvulsant, (2) history of adverse event with a generic formulary anticonvulsant, or (3) generic formulary anticonvulsants are contraindicated. |
|-----------------|--|

# ANTIDEPRESSANTS

---

## Products Affected

### Step 2:

- AUVELITY TABLET EXTENDED RELEASE 45-105 MG ORAL
- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- MARPLAN TABLET 10 MG ORAL
- TRINTELLIX TABLET 10 MG ORAL
- TRINTELLIX TABLET 20 MG ORAL
- TRINTELLIX TABLET 5 MG ORAL

## Details

---

|                 |  |
|-----------------|--|
| <b>Criteria</b> | Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of any generic formulary antidepressant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary antidepressant, (2) history of adverse event with a generic formulary antidepressant, or (3) generic formulary antidepressants are contraindicated. |
|-----------------|--|

---

Formulary ID: 24452 version 10  
Last Updated: 04/01/2024  
Effective: 04/01/2024

H1993\_Formulary\_2024\_C

# ATYPICALS

## Products Affected

### Step 2:

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL
- VERSACLOZ SUSPENSION 50 MG/ML ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL
- ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR

## Details

|                 |  |
|-----------------|--|
| <b>Criteria</b> | Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of 2 generic formulary agents in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) diagnosis that is not covered by 2 generic formulary agents, (2) history of inadequate treatment response with 2 generic formulary agents, (3) history of adverse event with 2 generic formulary agents, or (4) 2 generic formulary agents are contraindicated. |
|-----------------|--|

Formulary ID: 24452 version 10

Last Updated: 04/01/2024

Effective: 04/01/2024

H1993\_Formulary\_2024\_C

# RYTARY

---

## Products Affected

### Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

## Details

---

| Criteria | Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of generic Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone, (2) history of adverse event with Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone, or (3) Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone is contraindicated. |
|----------|---|
|----------|---|

## Index

### A

APTIOM TABLET 200 MG ORAL..... 1  
APTIOM TABLET 400 MG ORAL..... 1  
APTIOM TABLET 600 MG ORAL..... 1  
APTIOM TABLET 800 MG ORAL..... 1  
AUVELITY TABLET EXTENDED  
RELEASE 45-105 MG ORAL ..... 2

### D

DILANTIN CAPSULE 30 MG ORAL ..... 1

### E

EMSAM PATCH 24 HOUR 12 MG/24HR  
TRANSDERMAL..... 2  
EMSAM PATCH 24 HOUR 6 MG/24HR  
TRANSDERMAL..... 2  
EMSAM PATCH 24 HOUR 9 MG/24HR  
TRANSDERMAL..... 2

### F

FANAPT TABLET 1 MG ORAL ..... 3  
FANAPT TABLET 10 MG ORAL ..... 3  
FANAPT TABLET 12 MG ORAL ..... 3  
FANAPT TABLET 2 MG ORAL ..... 3  
FANAPT TABLET 4 MG ORAL ..... 3  
FANAPT TABLET 6 MG ORAL ..... 3  
FANAPT TABLET 8 MG ORAL ..... 3  
FANAPT TITRATION PACK TABLET 1  
& 2 & 4 & 6 MG ORAL..... 3  
FYCOMPA SUSPENSION 0.5 MG/ML  
ORAL..... 1  
FYCOMPA TABLET 10 MG ORAL..... 1  
FYCOMPA TABLET 12 MG ORAL..... 1  
FYCOMPA TABLET 2 MG ORAL..... 1  
FYCOMPA TABLET 4 MG ORAL..... 1  
FYCOMPA TABLET 6 MG ORAL..... 1  
FYCOMPA TABLET 8 MG ORAL..... 1

### L

LYBALVI TABLET 10-10 MG ORAL ..... 3  
LYBALVI TABLET 15-10 MG ORAL ..... 3  
LYBALVI TABLET 20-10 MG ORAL ..... 3  
LYBALVI TABLET 5-10 MG ORAL ..... 3

### M

MARPLAN TABLET 10 MG ORAL ..... 2

### R

RYTARY CAPSULE EXTENDED  
RELEASE 23.75-95 MG ORAL ..... 4  
RYTARY CAPSULE EXTENDED  
RELEASE 36.25-145 MG ORAL ..... 4  
RYTARY CAPSULE EXTENDED  
RELEASE 48.75-195 MG ORAL ..... 4  
RYTARY CAPSULE EXTENDED  
RELEASE 61.25-245 MG ORAL ..... 4

### S

SECUADO PATCH 24 HOUR 3.8  
MG/24HR TRANSDERMAL ..... 3  
SECUADO PATCH 24 HOUR 5.7  
MG/24HR TRANSDERMAL ..... 3  
SECUADO PATCH 24 HOUR 7.6  
MG/24HR TRANSDERMAL ..... 3  
SPRITAM TABLET DISINTEGRATING  
SOLUBLE 1000 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
SOLUBLE 250 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
SOLUBLE 500 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
SOLUBLE 750 MG ORAL ..... 1  
SYMPAZAN FILM 10 MG ORAL..... 1  
SYMPAZAN FILM 20 MG ORAL..... 1  
SYMPAZAN FILM 5 MG ORAL..... 1

### T

TRINTELLIX TABLET 10 MG ORAL..... 2  
TRINTELLIX TABLET 20 MG ORAL..... 2  
TRINTELLIX TABLET 5 MG ORAL..... 2

### V

VALTOCO 10 MG DOSE LIQUID 10  
MG/0.1ML NASAL..... 1  
VALTOCO 15 MG DOSE LIQUID  
THERAPY PACK 7.5 MG/0.1ML  
NASAL ..... 1

Formulary ID: 24452 version 10

Last Updated: 04/01/2024

Effective: 04/01/2024

H1993\_Formulary\_2024\_C

VALTOCO 20 MG DOSE LIQUID  
 THERAPY PACK 10 MG/0.1ML  
 NASAL ..... 1  
 VALTOCO 5 MG DOSE LIQUID 5  
 MG/0.1ML NASAL..... 1  
 VERSACLOZ SUSPENSION 50 MG/ML  
 ORAL..... 3  
 VRAYLAR CAPSULE 1.5 MG ORAL ..... 3  
 VRAYLAR CAPSULE 3 MG ORAL ..... 3

VRAYLAR CAPSULE 4.5 MG ORAL ..... 3  
 VRAYLAR CAPSULE 6 MG ORAL ..... 3  
 VRAYLAR CAPSULE THERAPY PACK  
 1.5 & 3 MG ORAL ..... 3  
**Z**  
 ZYPREXA RELPREVV SUSPENSION  
 RECONSTITUTED 210 MG  
 INTRAMUSCULAR ..... 3